(1) Overview of the precision drug delivery device industry
Commonly used clinical routes of administration include gastrointestinal administration (oral, sublingual and rectal administration), injection administration (intravenous, intramuscular and subcutaneous injection, etc.), as well as inhalation, nasal administration, and local administration. Among them, injection administration is widely used because of its fast absorption of drugs and accurate dosage into the body.
The above-mentioned conventional injection administration method has the following disadvantages: The clinical operation is more cumbersome, the requirements for the operator are relatively high, and professional medical knowledge and clinical operation experience are required, and can only be operated by professional medical personnel; During the opening of ampoules and vials, there will be a risk of glass fragments and microbial contamination in the air; The accuracy of the injection dose is not high, and it is impossible to implement precise drug delivery; When long-term use is required, patient compliance (i.e., the degree of obedience to the use of drugs prescribed by doctors) is lower, especially in children and elderly patients; A large amount of medical waste is generated, which requires huge manpower and material resources to deal with.
With the prosperity of the social economy and the improvement of people's living standards, bad behaviors and living habits lead to a variety of thingsChronic diseases (cardiovascular and cerebrovascular diseases: hypertension, hyperlipidemia, coronary heart disease, strokeWait; Metabolic Diseases:Obesity, diabetes, gout, iron deficiency anemia, osteoporosisDue to the current injection administration method needs to be operated by medical staff, the increasing number of patients with chronic diseases has formed a serious contradiction with limited medical resources, and there is an urgent need to facilitate patients to self-inject and administer drugs to solve the increasingly serious shortage of medical resources and reduce the daily administration of patients.
Time cost and material cost. With the development of drug research and development, drug packaging materials and other fields, a precise drug delivery method of self-subcutaneous injection using pen injectors for cartridge bottles and cans has been quickly recognized by patients.
(2) Market demand analysis of precision drug delivery device industry
The global pharmaceutical market consists of two major segments: chemical drugs and biological drugs. Biological drugs are the main direction of innovation in the current pharmaceutical market, which are widely used in chronic diseases such as cardiovascular and cerebrovascular diseases and metabolic diseases, and have a higher degree of compatibility with the new delivery method of self-injection administration; Biopharmaceuticals are generally in terms of compositionProteins, nucleic acids, sugars, lipidsand other unstable biological macromolecules, which have higher requirements in terms of dose accuracy and drug preservation. Based on the above reasons, biopharmaceuticals are the main downstream market for precision drug delivery devices represented by injection pens, and the development of the biopharmaceutical industry has a significant driving effect on the market demand for injection pens. The following is mainly for the market demand analysis of biological drugs and related indications.
Overview of the biopharmaceutical industry
Compared with chemical drugs, biological drugs have better efficacy and smaller curative effects, and can also deal with incurable diseases that were difficult to solve in the past, and have become the darling of the pharmaceutical market and the preferred choice of patients. According to Frost & Sullivan statistics, 7 of the 10 best-selling drugs in the world in 2019 are biologics, and innovative biopharmaceuticals provide a new choice for tumors, heart failure, Alzheimer's disease and other complex, refractory and undertreated diseases.
With the further development of technology and the further expansion of drug types in the biopharmaceutical industry, the biopharmaceutical industry will maintain good development prospects in the future. According to a research report published by Frost & Sullivan, the global biologics market size was approximately USD 286.4 billion in 2019, and the biologics market is expected to grow faster than the overall pharmaceutical market, reaching USD 456.7 billion by 2024, at a CAGR of 98%。
China's biopharmaceutical market started late, but due to the clinical safety, efficacy and compliance of biologics, the market demand for biopharmaceuticals in China has expanded rapidly. On the consumer side, with China's gradual entry into an aging society and the enhancement of social and economic consumption capacity, the overall demand for medical care in society is rising. On the production side, in recent years, China's policy support, technological progress and other factors have driven the rapid development of China's biopharmaceutical market, and the market size of biopharmaceuticals has increased from 116.7 billion yuan in 2014 to 262.2 billion yuan in 2018, and is expected to reach 635.7 billion yuan by 2023, with a compound annual growth rate of 224% and 194%, far exceeding the growth rate of the chemical and traditional Chinese medicine market.
In addition to the increase in the market share of biooriginal drugs, after the expiration of the patent of biooriginal drugs, biosimilars with similar efficacy will quickly seize a certain market space with the best advantage, and the overall decline of drugs will also reduce the drug burden of patients and further expand the market of such drugs. According to the Frost & Sullivan report, the size of China's biosimilar market reached 800 million yuan in 2014, reached 6.4 billion yuan in 2020, and is expected to reach 59 billion yuan in 2030.
To sum up, the future development prospects of China's biopharmaceutical industry are good, and new biological drugs are emerging one after another, which brings a market foundation for the precision drug delivery devices supporting biological drugs.
Segment the drug market
At present, injection pens are mainly used in the subcutaneous injection administration of various biological drugs, such as:Recombinant human growth hormone (short stature medication), insulin and analogues (diabetes medication), GLP-1 drugs (diabetes medication), teriparatide (osteoporosis medication), recombinant human follicle stimulating hormone (infertility medication), apomorphine (Parkinson's disease medication).and other chronic disease drugs that require medium and long-term self-medication, andAdalimumab, alixirumaband other ** targeted drugs, as well as high-end beauty needles and other consumer markets.
The analysis of the main drug segments is as follows:
a.Growth Hormone Market
At present, the incidence of short stature in children in China is about 3%. The best age group to use HGH** is 4 to 15 years old, and according to the 2019 National Population Survey, the population in this age group is about 1800 million people, corresponding to about 5.4 million people with short stature. Lack of growth hormone is the main cause of short stature, and recombinant human growth hormone is the most important means of short stature in recent years, and has become the most effective drug for short stature in recent years.
According to the research report of Tianfeng**, China's growth hormone market is in a stage of rapid expansion, with a compound growth rate of 21 from 2015 to 20209%。According to the research report of Guosheng**, the domestic growth hormone market size in 2019 is about 5.5 billion yuan, and the potential market space of China's growth hormone market is 135.9 billion yuan.
For specific subdivision drugs, growth hormone is divided into water injection, powder injection and long-acting dosage forms, of which both water injection and long-acting dosage forms need to be injected with an injection pen. At present, water injection dosage form is the mainstream choice, accounting for 70% of the growth hormone sales market in 20209%, and the long-acting dosage form that is more convenient to use and better patient experience is the future development direction, so the growth of the growth hormone drug market can significantly drive the demand for injection pens. In the domestic growth hormone drug market, Kinsey Pharmaceutical is the industry leader, with a market share of 7613%, which is mainly in water injection dosage form, and is the only long-acting dosage form manufacturer, and the remaining market is mainly occupied by Anke biological powder injection and United Searle powder injection.
b.Hypoglycemic drugs market
According to the IDF World Diabetes Map (10th Edition) published by the International Diabetes Federation (IDF), in 2021 there were about 53.7 billion adults (aged 20-79) have diabetes (1 in 10 people have diabetes); 1 in 2 people with diabetes is undiagnosed, making a total of 24 billion people.
Due to the aggravation of the aging of the population, the difference in the physique, the improvement of living standards and the influence of unhealthy lifestyle, the Chinese population belongs to the susceptible population to diabetes, and the situation of diabetes prevention and treatment is becoming increasingly severe, and the number of people with the incidence of diabetes is increasing year by year. The IDF estimates that 1 in 4 people with diabetes in the world is from China, and 1 in ChinaThere are 4.1 billion adults with diabetes, with an age-appropriate prevalence of about 106%。The base of diabetic patients in China is large, the proportion of undiagnosed diabetes is high, and the awareness rate is low.
Under the current medical conditions, the vast majority of diabetic patients have irreversible conditions and require long-term or even lifelong life**. According to the Clinical Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus in China (2020 Edition), patients with type 1 diabetes need to rely on insulin** to maintain their lives; Patients with type 2 diabetes who do not respond well to oral hypoglycemic drugs or have contraindications to oral medications still require insulin to control hyperglycemia and reduce the risk of diabetes complications; At some point, especially if the disease is prolonged, insulin** may be the mainstay, if not necessary, blood sugar control measure. With the listing of domestic insulin and its analogues, as well as the inclusion of insulin products in the Medical Insurance Catalogue, the economic burden of insulin** in diabetic patients has been significantly reduced, thereby further releasing the market demand for insulin and analogues.
At present, new methods of lowering blood sugar include:glp-1ra **, including:Exenatide, liraglutide, risinatide, benaglutide, dulaglutide, losenatide, semaglutideWait; GLP-1RA can effectively lower blood glucose, partially restore pancreatic islet cell function, reduce body weight, improve blood lipid profile and lower blood pressure, and has a low risk of hypoglycemia, making it an emerging choice for diabetes**. According to the Clinical Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus in the Elderly in China (2022 Edition), GLP-1RA is the preferred injectable hypoglycemic drug for elderly diabetic patients with heart and kidney disease or who need to lose weight.
Among diabetic patients in China, the proportion of overweight is 41%, and the proportion of obesity is 243%, cardiovascular disease is the first complication of diabetes, so GLP-1 drugs with the best and heart-protecting drugs have great market potential in China. According to the research report "GLP-1 Leads the Era of Global Hypoglycemic Drugs", the market share of GLP-1 drugs in the world reached 19% in 2019, and it has remained as high as 39 in the past decadeThe high-speed compound growth rate of 7% is the priority to recommend drugs; Due to the influence of high ** and low level of awareness, the market share of the domestic market is only 3%, and there is a lot of room for improvement.
At present, some GLP-1 drugs have been included in the medical insurance or patent expired, generic drugs will be marketed in large quantities in the next 2-3 years, and self-developed GLP-1 drugs have also emerged, thus promoting the rapid increase of the market share of GLP-1 drugs in China. The pegylated losenatitide independently developed by the domestic company Haosen Pharmaceutical was approved for marketing in 2019, which is the first long-acting GLP-1RA independently developed in China, which can be injected once a week, and the drug is expected to break the monopoly of foreign pharmaceutical companies GLP-1RA in China.
Compared with oral hypoglycemic drugs**, insulin** and GLP-1RA** are mainly self-injection**, which requires patients and their caregivers to master more self-management skills, and have a strong correlation with the injection pen market. With the improvement of the diagnosis and treatment rate of diabetic patients and the decline of drugs, it is expected that the market for insulin and analogues and GLP-1 drugs in China will continue to grow, especially the GLP-1 drugs are expected to increase rapidly, which will bring great new demand to China's injection pen market.
c.Teriparatide drug market
According to the results of the epidemiological survey of osteoporosis in China released by the National Health Commission in 2018, osteoporosis has become an important health problem for people over 50 years old in China, and osteoporosis is especially serious in middle-aged and elderly women. The prevalence of osteoporosis in people over 50 years of age is 192%, including 6 for men0% and 32 for women1%。The survey also found that there is a large number of people with low bone mass in China, and the low bone mass rate of people over 50 years old is 464%, which is a high-risk group for osteoporosis.
Teriparatide is a bone formation promoter, which can regulate bone metabolism and the body's absorption of calcium and phosphorus and other osteogenic substances, and is recognized as one of the ideal drugs for osteoporosis.
According to the research report of AVIC**, the original research company of teriparatide is Eli Lilly, and Eli Lilly achieved sales revenue of 14 percent worldwide in 2019US$0.5 billion, in contrast, teriparatide is still in its infancy in the Chinese market, with sales of about 21 million yuan in sample hospitals in 2019, and there are only three companies selling teriparatide in China's market: United Searle, Salubris and Eli Lilly.
Salubris' teriparatide powder injection was launched in 2019, and the more convenient water injection (i.e., the dosage form using a pen injector) was approved for marketing in April 2022, which is expected to form a strong alternative to Eli Lilly's teriparatide original drug in the future, and further increase the audience and overall market space of teriparatide drugs.
d.Market for follicle-stimulating hormone drugs
Follicle-stimulating hormone (FSH) is an important assisted reproductive drug, which is mainly used to promote follicle growth and development, thereby assisting infertility. In recent years, the number of infertility patients in China has increased significantly, according to the data of the Prospective Industry Research Institute and CCTV news reports, the infertility rate in China in 1995 was only about 3%, and from 2012 to 2018, the number of infertility in China rose rapidly from 40 million to 50 million, and the overall infertility rate reached 1445%, and the infertility rate of couples of childbearing age in China has climbed to about 12%-18%. At present, the penetration rate of follicle-stimulating hormone in China is low, and there is still a large market space for the domestic follicle-stimulating hormone market.
According to the data of the Toubao Research Institute and **, the market size of the follicle-stimulating hormone industry from 2014 to 2018 increased from 14200 million yuan increased to 23700 million yuan, with an average annual compound growth rate of 136%。The follicle-stimulating hormone market will further expand in the future, and the market size is expected to reach 46700 million yuan. At the same time, the successive implementation of the two-child and three-child policies in China has increased the willingness of post-70s and post-80s families to have children again, and the number of elderly women with reproductive needs is increasing, and the demand for assisted reproduction of elderly women will stimulate the further growth of the follicle-stimulating hormone market.
In addition, the trend of localization and substitution of follicle-stimulating hormone will help domestic related biopharmaceutical companies to further expand. Since the listing of recombinant follicle-stimulating hormone, the global follicle-stimulating hormone market has been dominated by Merck KGaA's Merck (acquired the recombinant follicle-stimulating hormone market after the acquisition of Organon) and Merck Serono, and the domestic market is mainly dominated by foreign-funded enterprises. The approval of domestic recombinant follicle-stimulating hormone such as Kinsey Pharmaceutical, Alphamab Oncology and other domestic recombinant follicle-stimulating hormone has broken the long-standing situation of follicle-stimulating hormone being controlled by foreign-funded enterprises.
With the gradual increase of domestic recombinant follicle-stimulating hormone and the clinical trial of long-acting follicle-stimulating hormone, it is expected that the cost of recombinant follicle-stimulating hormone will be further reduced in the future, which is conducive to the further expansion of the recombinant follicle-stimulating hormone market and the simultaneous growth of the demand for injection pens.
The overall market demand for precision drug delivery devices
As mentioned above, the downstream industry of precision drug delivery devices is in a period of rapid development of the industry, and the future market space is large. According to the reportlinker study, the global injection pen market size is expected to be $37.6 billion in 2021, and the global injection pen market size will reach $53.3 billion in 2026, with a compound annual growth rate of 72%。China's injection pen market started late, but with the intensification of China's aging population and the increase in the number of patients with chronic diseases, the rich functions, good use experience and injection effect of injection pens ensure the compliance of patients, so that the demand for injection pens will continue to grow.
Chapter 1 Overview of the Development of Drug Delivery Device Industry
1.1 Introduction to the drug delivery device industry.
1.1.1. Definition and characteristics of the industry.
1.1.2 Overview of industry development.
1.1.3 The industrial chain picture of the drug delivery device industry.
1.2 Introduction to the product categories of the drug delivery device industry.
1.3 Introduction to the main application fields of the drug delivery device industry.
1.4 Global Drug Delivery Device Industry Market Size, 2018-2029.
1.5 Market size of China's drug delivery device industry from 2018 to 2029.
Chapter 2 Analysis of the Operating Environment (PEST) of the Drug Delivery Device Industry at Home and Abroad
2.1 Analysis of the political and legal environment of the drug delivery device industry.
2.2 Analysis of the economic environment of the drug delivery device industry.
2.2.1 Analysis of the global macroeconomic situation.
2.2.2 Analysis of China's macroeconomic situation.
2.2.3. Analysis of the macroeconomic environment of the industry.
2.3 Analysis of the social environment of the drug delivery device industry.
2.4 Technical environment analysis of the drug delivery device industry.
Chapter 3 Development Status of Global and Chinese Drug Delivery Device Industry
3.1 The development status of the global drug delivery device industry.
3.1.1 Analysis of the development of the global drug delivery device industry.
3.1.2 Global Drug Delivery Device Industry Market Size, 2018-2022.
3.2 Global Drug Delivery Device Industry Concentration Analysis.
3.3 Impact of the pandemic on the global drug delivery device industry.
3.4 Analysis of the development status of China's drug delivery device industry.
3.4.1 Analysis of the development of China's drug delivery device industry.
3.4.2 Policy environment for China's drug delivery device industry.
3.4.3 The impact of the new crown epidemic on the development of China's drug delivery device industry.
3.5 Market size of China's drug delivery device industry.
3.6 Concentration analysis of China's drug delivery device industry.
3.7 Import and export analysis of China's drug delivery device industry.
3.8 Analysis of the pain points of the drug delivery device industry development.
3.9 Analysis of development opportunities in the drug delivery device industry.
Chapter 4 Global Drug Delivery Device Industry Market Segment Market Analysis
4.1 Global Drug Delivery Device Industry Market Size by Segment Type.
4.1.1 Statistics on global blood group sales, sales and growth rate.
4.1.2 Statistics on global expansion sales, sales and growth rate.
4.1.3 Statistics of global professional sales volume, sales and growth rate.
4.1.4 Global secondary sales volume, sales and growth rate statistics.
4.1.5 Global other sales volume, sales and growth rate statistics.
4.2 Global Drug Delivery Device Industry Segment Market ** Changes.
4.3 Factors influencing the product segmentation of the global drug delivery device industry**.
Chapter 5 Market Analysis of Segmentation Types of China's Drug Delivery Device Industry
5.1 Market size of China's drug delivery device industry by segment.
5.1.1 Statistics of blood group sales, sales and growth rate in China.
5.1.2 Statistics of China's expanded sales volume, sales and growth rate.
5.1.3 Statistics of China's professional sales volume, sales and growth rate.
5.1.4 Statistics of secondary sales volume, sales and growth rate in China.
5.1.5 Other sales volume, sales and growth rate statistics in China.
5.2 Changes in the market segment of China's drug delivery device industry.
5.3 Factors influencing product segments in China's drug delivery device industry.
Chapter 6 Global Drug Delivery Device Industry Downstream Application Market Analysis
6.1 Global Drug Delivery Devices Market Size by Application Segment.
6.1.1 Statistics of global drug delivery device sales, sales and growth rate in the clinic sector.
6.1.2 Statistics of global drug delivery device sales, sales and growth rate in the hospital sector.
6.2 The impact of fluctuations in upstream industry factors on the drug delivery device industry.
6.3 Impact of the development of downstream application industries on the drug delivery device industry.
Chapter 7 Market Analysis of Downstream Application Fields of China's Drug Delivery Device Industry
7.1 Market size of drug delivery devices in China by application.
7.1.1 Statistics of sales volume, sales and growth rate of drug delivery devices in the clinic sector in China.
7.1.2 Statistics of sales volume, sales and growth rate of drug delivery devices in the hospital sector in China.
7.2 The impact of fluctuations in upstream industry factors on the drug delivery device industry.
7.3 Impact of the development of downstream application industries on the drug delivery device industry.
Chapter 8 Analysis of the Development Status of the Drug Delivery Device Industry in Major Regions and Countries of the World
8.1 Global Drug Delivery Device Industry Market Sales Analysis by Major Regions.
8.2 Global Drug Delivery Device Industry Market Sales Analysis by Key Regions.
8.3 Analysis of the development trend of the drug delivery device industry in the Asia-Pacific region.
8.3.1 Impact of the pandemic on the drug delivery device industry in Asia-Pacific.
8.3.2 Asia-Pacific Drug Delivery Device Industry Market Size Analysis.
8.3.3 Drug delivery device industry market size statistics of major countries in Asia-Pacific region.
8.3.3.1 Drug delivery device industry sales volume and value by major countries in Asia-Pacific.
8.3.3.2 Market size analysis of China's drug delivery device industry.
8.3.3.3 Japan Drug Delivery Device Industry Market Size Analysis.
8.3.3.4 South Korea Drug Delivery Device Industry Market Size Analysis.
8.3.3.5 India Drug Delivery Device Industry Market Size Analysis.
8.3.3.6 Drug delivery device industry market size analysis in Australia and New Zealand.
8.3.3.7 ASEAN Drug Delivery Device Industry Market Size Analysis.
8.4 Analysis of the development trend of the drug delivery device industry in North America.
8.4.1 Impact of the pandemic on the drug delivery device industry in North America.
8.4.2 Drug Delivery Device Industry Market Size Analysis in North America.
8.4.3 Drug delivery device industry market size statistics by major countries in North America.
8.4.3.1 Drug delivery device industry sales volume and value by major countries in North America.
8.4.3.2 U.S. Drug Delivery Device Industry Market Size Analysis.
8.4.3.3 Market size analysis of Canada's drug delivery device industry.
8.4.3.4 Mexico Drug Delivery Device Industry Market Size Analysis.
8.5 Analysis of the development trend of the drug delivery device industry in Europe.
8.5.1 Impact of the pandemic on the drug delivery device industry in Europe.
8.5.2 Drug delivery device industry market size analysis in Europe.
8.5.3 Drug delivery device industry market size statistics of major countries in Europe.
8.5.3.1 Drug delivery device industry sales volume and sales by major countries in the European region.
8.5.3.1 Market size analysis of the drug delivery device industry in Germany.
8.5.3.2 UK Drug Delivery Device Industry Market Size Analysis.
8.5.3.3 France Drug Delivery Device Industry Market Size Analysis.
8.5.3.4 Italy Drug Delivery Device Industry Market Size Analysis.
8.5.3.5 Spain Drug Delivery Device Industry Market Size Analysis.
8.5.3.6 Market size analysis of the Russian drug delivery device industry.
8.5.3.7 Impact of the Russia-Ukraine War on the development of the drug delivery device industry in Russia.
8.6 Analysis of the development trend of the drug delivery device industry in the Middle East and Africa.
8.6.1 Impact of the pandemic on the drug delivery device industry in the Middle East and Africa.
8.6.2 Drug delivery device industry market size analysis in the Middle East and Africa region.
8.6.3 Drug delivery device industry market size statistics of major countries in the Middle East and Africa region.
8.6.3.1 Drug delivery device industry sales volume and sales in key countries in the Middle East and Africa region.
8.6.3.2 South Africa Drug Delivery Device Industry Market Size Analysis.
8.6.3.3 Egypt Drug Delivery Device Industry Market Size Analysis.
8.6.3.4 Iran Drug Delivery Device Industry Market Size Analysis.
8.6.3.5 Saudi Arabia Drug Delivery Device Industry Market Size Analysis.
Chapter 9 Analysis of the Global and China Drug Delivery Device Industry Market Competition Landscape
9.1 Major manufacturers in the global drug delivery device industry.
9.2 Major manufacturers in China's drug delivery device industry.
9.3 The market position of China's drug delivery device industry in the global competitive landscape.
9.4 Analysis of the competitive advantages of China's drug delivery device industry.
Chapter 10 Analysis of Key Companies in the Global Drug Delivery Device Industry
10.1 baxter
10.1.1 Introduction to Baxter's basic information.
10.1.2 Introduction to Baxter's main products and services.
10.1.3 Analysis of Baxter's production and operation.
10.1.4 Baxter competitive advantages and disadvantages analysis.
10.2 b braun
10.2.1 b Introduction to basic information about BRAUN.
10.2.2 b Introduction to Braun's main products and services.
10.2.3 b Analysis of BRAUUN's production and operation.
10.2.4 b Analysis of the competitive advantages and disadvantages of BRAUN.
10.3 merit pharmaceutical
10.3.1 Introduction to the basic information of Merit Pharmaceutical.
10.3.2 Introduction to Merit Pharmaceutical's main products and services.
10.3.3 Analysis of Merit Pharmaceutical's production and operation.
10.3.4 Merit Pharmaceutical's competitive advantages and disadvantages analysis.
10.4 kawasumi
10.4.1 Introduction to kawasumi basic information.
10.4.2 Introduction to kawasumi's main products and services.
10.4.3 Analysis of kawasumi's production and operation.
10.4.4 Analysis of Kawasumi's competitive advantages and disadvantages.
10.5 bd
10.5.1 Introduction to BD basic information.
10.5.2 Introduction of BD's main products and services.
10.5.3. Analysis of BD production and operation.
10.5.4 Analysis of BD competitive advantages and disadvantages.
10.6 fresenius kabi
10.6.1 Introduction to Fresenius Kabi Basic Information.
10.6.2 Introduction to Fresenius Kabi's main products and services.
10.6.3 Analysis of the production and operation of Fresenius Kabi.
10.6.4 Analysis of the competitive advantages and disadvantages of Fresenius Kabi.
10.7 medtronic
10.7.1 Introduction to the basic information of medtronic.
10.7.2 Introduction to Medtronic's main products and services.
10.7.3 Analysis of the production and operation of Medtronic.
10.7.4 Competitive advantages and disadvantages analysis of medtronic.
10.8 hospira
10.8.1 Introduction to Hospira.
10.8.2 Introduction to Hospira's main products and services.
10.8.3 Analysis of Hospira's production and operation.
10.8.4 Hospira Competitive Strengths and Weaknesses Analysis.
10.9 smiths medical
10.9.1 Basic information about Smiths Medical.
10.9.2 Introduction to Smiths Medical's main products and services.
10.9.3 Analysis of the production and operation of Smiths Medical.
10.9.4 Smiths Medical Competitive Strengths and Weaknesses Analysis.
Chapter 11 Global Drug Delivery Device Industry Market Development under the Current International Situation**
11.1 Global Drug Delivery Devices Industry Market Size**.
11.1.1 Global Drug Delivery Devices Industry Volume, Value, and Growth Rate**.
11.2 Global Drug Delivery Device Segment Type Market Size**.
11.2.1 Global Drug Delivery Devices Industry Sales Volume by Segment**.
11.2.2 Global Drug Delivery Devices Industry Segment Sales**.
11.2.3 Global Drug Delivery Device Industry by Product 2023-2029***
11.3 Global Drug Delivery Devices Market Size by Application**.
11.3.1 Global drug delivery device sales by application**.
11.3.2 Global drug delivery device sales by application**.
11.4 Development trend of drug delivery device industry in key regions of the world.
11.4.1 Sales volume of drug delivery device industry in key regions around the world**.
11.4.2 Global drug delivery device industry sales in key regions**.
Chapter 12 Market Development of China's Drug Delivery Device Industry under the 14th Five-Year Plan**
12.1 "14th Five-Year Plan" drug delivery device industry related policies.
12.2 Market size of China's drug delivery device industry**.
12.3 Market size of drug delivery device segment in China**.
12.3.1 Sales volume of drug delivery device industry segment in China**.
12.3.2 China Drug Delivery Device Industry Segment Type Sales**.
12.3.3 2023-2029 China drug delivery device industry by product***
12.4 Market size of drug delivery devices in China by application field**.
12.4.1 Sales volume of drug delivery devices by application in China**.
12.4.2 Sales of drug delivery devices in China by application**.